期刊
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 14, 期 2, 页码 107-113出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2013.10.002
关键词
Angiogenesis; Anti-VEGF; Chemotherapy; Mantle cell lymphoma; Tumor microenvironment
资金
- ASCO Career Development Award
- NIH [K08HL091517]
- Lymphoma Research Foundation grant
- Lymphoma Foundation
- Clinical Translational Science Center [2UL1TR000457-06]
We report the long-term follow-up of the first phase II trial of R-CHOP (rituximab-cyclophosphamide, adriamycin, vincristine, and prednisone) plus bevacizumab in previously untreated mantle cell lymphoma (MCL) patients. Eleven patients received bevacizumab at 15 mg/kg on day 1, and standard R-CHOP on day 3 each cycle for 6 cycles. The addition of bevacizumab did not appear to significantly improve efficacy beyond that observed from previous studies with R-CHOP alone. Background: Emerging evidence indicates that MCL has increased angiogenesis within the tumor microenvironment. We initiated a phase II trial to determine if the addition of bevacizumab to the standard R-CHOP regimen could enhance antitumor effects in patients with previously untreated MCL. Patients and Methods: Eleven patients with previously untreated MCL received bevacizumab at 15 mg/kg on day 1, and standard CHOP-21 (CHOP given every 21 days per cycle) with rituximab (375 mg/m(2) per cycle) on day 3 of each cycle for a total of 6 cycles. Planned study end points included safety and efficacy assessment, and exploratory analysis of angiogenic profiles. The study was suspended in August of 2010 based on safety findings in DLBCL (diffuse large B-cell lymphoma) of increased cardiovascular events with the regimen. Results: Beyond the standard R-CHOP safety profile, Grade 3 left ventricular dysfunction developed in 2 patients (18%), Grade 1/2 hypertension, proteinuria, and bleeding each developed in 1 patient (9%). The overall response rate was 82% with 36% complete response (CR)/complete response unconfirmed (CRu). The median progression-free survival (n = 11) was 18 months (95% confidence interval, 3-not reached), and 3-year overall survival rate was 82%. Correlative studies showed increased vascular endothelial growth factor receptor 1 expression in tumor cells at baseline, and elevated levels of plasma vascular endothelial growth factor (VEGF) throughout treatment. Conclusion: The addition of bevacizumab to the standard R-CHOP regimen did not appear to significantly improve efficacy beyond that observed from previous studies using R-CHOP alone. Therapeutic strategies that provide sustained inhibition on VEGF-related and VEGF-independent targets within the tumor microenvironment might further improve antiangiogenic effects and warrant further exploration in MCL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据